Hot Investor Mandate: China-Based Corporation Seeks Strategic Investment & Partnership Opportunities in Early-Stage Therapeutics in Cardiovascular Disease, Oncology, and More

16 Jul

Headquartered in China, a publicly traded corporation (SHA:600535) is dedicated to building a top-tier, modern, and international brand in pharmaceutical products. The firm provides modernized traditional Chinese medicines (TCMs), small molecule and biological drugs. The firm is actively pursuing strategic partnerships with pharmaceutical companies and bio-techs from domestic and overseas in the abovementioned therapeutic areas. The firm considers a board range of strategies including strategic investment, joint venture, acquisition, licensing, and co-development.

The firm is looking for strategic partnerships in chemical drugs and biological drugs. The firm is open to products at clinical to launched stages in therapeutic areas of cardiovascular, cerebrovascular diseases, oncology, diabetes, liver disease and so on.

The firm is looking to build collaborative partnerships with experienced teams in key strategic sectors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: